NASD · Healthcare · Biotechnology · USA
Acadia Pharmaceuticals Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Acadia Pharmaceuticals is a biopharmaceutical company with two core franchises treating neurological and rare diseases. Its commercial products include NUPLAZID for hallucinations and delusions associated with Parkinson's disease psychosis, and DAYBUE for Rett syndrome treatment. The company develops additional product candidates targeting conditions such as Alzheimer's disease psychosis and other neurological disorders, serving patients globally.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Acadia Pharmaceuticals Inc stock.
Slightly undervalued: intrinsic value $22.57 per share, market price $20.44, margin of safety 9.5% (as of 2026-10-20).
Discounting its cash flows at 9.5% (average of 3 methods) values the shares at $22.57; the price of $20.44 is 9% below that value.
Leak Score: 41/100 on 11 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
18 more in this industry show a wider margin of safety.
ACAD is slightly undervalued (as of the 2026-10-20 close). Discounting its cash flows at 9.5% (average of 3 methods) values the shares at $22.57; the price of $20.44 is 9% below that value.
$22.57 per share (as of the 2026-10-20 close), against a market price of $20.44. That is a margin of safety of 9.5%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
41 out of 100, which we rate "On Watch", on 11 of 12 value investing signals.